The estimated Net Worth of Mark A Reiley is at least $7.91 Million dollars as of 15 April 2019. Mark Reiley owns over 10,000 units of SI-BONE Inc stock worth over $7,738,754 and over the last 6 years Mark sold SIBN stock worth over $169,500.
Mark has made over 1 trades of the SI-BONE Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Mark sold 10,000 units of SIBN stock worth $169,500 on 15 April 2019.
The largest trade Mark's ever made was selling 10,000 units of SI-BONE Inc stock on 15 April 2019 worth over $169,500. On average, Mark trades about 5,000 units every 0 days since 2018. As of 15 April 2019 Mark still owns at least 513,180 units of SI-BONE Inc stock.
You can see the complete history of Mark Reiley stock trades at the bottom of the page.
Mark's mailing address filed with the SEC is C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA, CA, 95050.
Over the last 6 years, insiders at SI-BONE Inc have traded over $114,943,926 worth of SI-BONE Inc stock and bought 1,250,000 units worth $18,750,000 . The most active insiders traders include David P Bonita, Advisors Llc Orbi Med Capit... und John Gordon Freund. On average, SI-BONE Inc executives and independent directors trade stock every 8 days with the average trade being worth of $401,535. The most recent stock trade was executed by Anshul Maheshwari on 3 September 2024, trading 1,414 units of SIBN stock currently worth $23,119.
si-bone® is focused on helping patients in one of the most under-served, under-diagnosed, and under-treated areas in orthopedics, the sacroiliac (si) joint. si-bone developed an innovative, patented implant to fuse the si joint. the ifuse implant system® provides a less invasive alternative to traditional sacroiliac (si) joint fusion surgery and has been used in over 25,000 procedures to date. the company is managed by an experienced team of executives from kyphon, medtronic, inbone, saint francis and several start up orthopedic and spine companies. the ifuse implant system is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. this includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. there are potential risks associated with the ifuse implant system. it may not be appropriate for al
SI-BONE Inc executives and other stock owners filed with the SEC include: